research use only

Levalbuterol tartrate Adrenergic Receptor modulator

Name: Levalbuterol tartrate
Brand: Selleck Chemicals
SKU: S3153
Rating: 5 (1 reviews)

Cat.No.S3153

Levalbuterol tartrate (Levosalbutamol tartrate) is a relatively selective beta2-Adrenergic Receptor agonist used for the treatment of asthma.

Chemical Structure

Molecular Weight: 628.71

Jump to

Quality Control

Batch: S315301 DMSO]100 mg/mL]false]Water]100 mg/mL]false]Ethanol]Insoluble]false Purity: 99.69%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS
Datasheet

99.69

Related Targets	AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other Adrenergic Receptor Inhibitors	ICI 118551 Hydrochloride (Zenidolol) L755507 Yohimbine HCl Atipamezole Naftopidil Detomidine HCl Higenamine hydrochloride Adrenalone HCl Medetomidine HCl Deoxycorticosterone acetate

Chemical Information, Storage & Stability

Molecular Weight	628.71	Formula	C₃₀H₄₈N₂O₁₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	661464-94-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Levosalbutamol tartrate			Smiles	CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O.C(C(C(=O)O)O)(C(=O)O)O

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (159.05 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vivo

Racemic albuterol (7.5 mg, bid) results in a greater improvement in their forced expiratory volume in 1 second (FEV1) as well as in their asthma scores after 1 hour of continuous treatment compared to the Levalbuterol (3.75 mg, bid) administration in children with asthma. The greater improvement in asthma scores is maintained after the second hour of continuous therapy in the racemic albuterol group but not for forced expiratory volume in 1 second (FEV1) measurements. Levalbuterol (1.25 mg) requires significantly fewer median total nebulizations and scheduled nebulizations compared with those in the racemic albuterol (2.5 mg) group in patients with asthma or chronic obstructive pulmonary disease (COPD). Disease symptom assessment and subject general well-being score scores improves significantly from baseline in both Levalbuterol (1.25 mg) and racemic albuterol (2.5 mg) treatment groups, and beta-mediated adverse effects mean scores are significantly greater with Levalbuterol versus racemic albuterol.

References

[1] https://pubmed.ncbi.nlm.nih.gov/21275850/
[2] https://pubmed.ncbi.nlm.nih.gov/18640474/
[3] https://pubmed.ncbi.nlm.nih.gov/20923385/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):